A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer

NCT00430235 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Prostate

Interventions

DRUG: BAY 43-9006

Sponsor

British Columbia Cancer Agency